---
document_datetime: 2024-11-13 11:49:40
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zoledronic-acid-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zoledronic-acid-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.6709712
conversion_datetime: 2025-12-28 12:50:21.543878
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zoledronic Acid Accord

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0015              | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                | 26/05/2023                          | n/a                                         |                                  |           |
| IB/0013              | B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of | 06/04/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             | a Member State - AS                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                 |                     |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------|
| IA/0012     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                    | 24/01/2022 | 16/12/2022 | Annex II and PL |                     |
| IB/0011     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                   | 14/09/2021 | 16/12/2022 | SmPC and PL     |                     |
| IB/0010     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                     | 23/09/2020 | 23/09/2021 | SmPC            |                     |
| IAIN/0009   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                               | 18/09/2019 | n/a        |                 |                     |
| IAIN/0008/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - control/testing | 19/03/2019 | 28/02/2020 | Annex II and PL | Not including batch |

<div style=\"page-break-after: always\"></div>

| T/0007    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                            | 28/01/2019   | 11/03/2019   | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0006    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                        | 20/09/2018   | 20/11/2018   | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zoledronic Acid Accord in the approved indications remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0005   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                   | 04/08/2017   | 02/08/2018   | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                       |
| IB/0004/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 02/08/2016   | 13/07/2017   | SmPC, Annex II and PL            |                                                                                                                                                                                                                                                                                       |
| IA/0003   | B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                              | 22/03/2016   | n/a          |                                  |                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| IB/0002   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by         | 06/11/2015   | 08/02/2016   | SmPC, Annex II and PL   | the MAH   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|-----------|
| IB/0001   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 10/02/2015   | 08/02/2016   | SmPC and PL             |           |